. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: J Cyst Fibros. 2019 Dec 20;19(4):632–640. doi: 10.1016/j.jcf.2019.12.007

Table 1.

Clinical characteristics of the cohorts at the time of sample collection

	Mild Cohort (n = 44) Mean (SD)	Severe Cohort (n = 44) Mean (SD)	P-value¹
FEV₁ % Predicted	111 (6.2)	90 (11.6)	<0.001
BMI percentile	60 (22)	42 (27)	<0.001
	N (%)	N (%)
MSSA infection	33 (75)	29 (66)	0.48
MRSA infection	6 (14)	15 (34)	0.04
Chronic macrolide use	15 (34)	26 (59)	0.02
Inhaled antibiotics	10 (23)	24 (55)	0.004
Dornase alfa use	37 (84)	41 (93)	0.31

SD: standard deviation, FEV₁: forced expiratory volume in 1 second; BMI: body mass index, MSSA: methicillin sensitive Staphylococcus aureus, MRSA: methicillin resistant S. aureus

Group differences by t-test and Fisher’s exact as appropriate.